GPCR · Insider trading · 13F holders · Congress trades
Structure Therapeutics Inc. (GPCR)
Who is buying and selling GPCR: company insiders on SEC Form 4, hedge funds and superinvestors on Form 13F, and members of Congress under the STOCK Act. Every figure links to the filing or page it comes from.
- 13F filers holding
- 34
- Insider buys, 90 days
- $0
- Insider sales, 90 days
- $0
- Congress trades, 12 months
- 1
GPCR at a glance
- No open-market insider purchases or sales of GPCR were filed in the last 90 days.
- 34 13F filers hold GPCR among their 50 largest positions, worth $1.5B combined, including Behzad Aghazadeh, James Flynn and Julian and Felix Baker. The biggest bets by portfolio weight are NEXTBio Capital Management LP (7.7%), Bvf Inc/il (4.6%) and B Group, Inc. (4.3%). In their latest 13Fs, 0 managers opened a new position and 15 added to one.
- Members of Congress have disclosed 1 GPCR trade since 2023, 0 purchases and 1 sale in the past year; the latest was Thomas R. Carper (D-DE), selling $1K–15K on Oct 4, 2023.
- GPCR last closed at $22.17 on Oct 30, 2026.
GPCR insider trading
No open-market insider purchases or sales of GPCR were filed in the last 90 days.
Who owns GPCR? Hedge funds and superinvestors
34 13F filers hold GPCR among their 50 largest positions, worth $1.5B combined, including Behzad Aghazadeh, James Flynn and Julian and Felix Baker. The biggest bets by portfolio weight are NEXTBio Capital Management LP (7.7%), Bvf Inc/il (4.6%) and B Group, Inc. (4.3%). In their latest 13Fs, 0 managers opened a new position and 15 added to one.
Superinvestors holding GPCR: Behzad Aghazadeh 3.2% · James Flynn 0.7% · Julian and Felix Baker 0.4%
| Manager | % of portfolio | Value | Shares | Last quarter | 13F |
|---|---|---|---|---|---|
| Behzad AghazadehHedge fund | 3.2% | $351.8M | 6,555,555 | +0.0% shares | Q2 2026 |
| Deep Track Capital, LPHedge fund | 3.7% | $254.4M | 4,740,072 | +10.8% shares | Q2 2026 |
| Bvf Inc/ilInvestment manager | 4.6% | $180.7M | 3,366,823 | -2.7% shares | Q2 2026 |
| Orbimed Advisors LLCHedge fund | 2.3% | $118.6M | 2,209,400 | +49.7% shares | Q2 2026 |
| Rtw Investments, LPHedge fund | 0.7% | $86.3M | 1,607,507 | — | Q2 2026 |
| Julian and Felix BakerHedge fund | 0.4% | $76.9M | 1,432,529 | +0.0% shares | Q2 2026 |
| Casdin Capital, LLCHedge fund | 3.2% | $63.1M | 1,175,000 | +0.0% shares | Q2 2026 |
| James FlynnHedge fund | 0.7% | $58.3M | 1,086,000 | +41.4% shares | Q2 2026 |
| Siren, L.L.C.Investment manager | 1.0% | $46.9M | 872,967 | -34.3% shares | Q2 2026 |
| Pacific Heights Asset Management LLCMutual fund manager | 1.4% | $42.9M | 800,000 | +6.7% shares | Q2 2026 |
| Rock Springs Capital Management LPHedge fund | 1.7% | $34.4M | 640,317 | +0.0% shares | Q2 2026 |
| Logos Global Management LPHedge fund | 1.2% | $26.8M | 500,000 | +0.0% shares | Q2 2026 |
| Parkman Healthcare Partners LLCHedge fund | 2.7% | $26.1M | 485,661 | +109.3% shares | Q2 2026 |
| Davern Capital Partners, LPInstitutional asset manager | 4.1% | $23.9M | 446,059 | +252.7% shares | Q2 2026 |
| NEXTBio Capital Management LPHedge fund | 7.7% | $16.8M | 312,496 | +134.5% shares | Q2 2026 |
| Catalio Capital Management, LPHedge fund | 2.8% | $14.8M | 276,550 | +8.3% shares | Q2 2026 |
| HSG Holding LtdInvestment manager | 1.2% | $14.3M | 266,062 | +0.0% shares | Q2 2026 |
| Eversept Partners, LPHedge fund | 0.6% | $10.5M | 196,302 | +42.2% shares | Q2 2026 |
| B Group, Inc.Hedge fund | 4.3% | $7.5M | 140,000 | +9.8% shares | Q2 2026 |
| HighVista Strategies LLCHedge fund | 1.6% | $7.0M | 130,784 | +5.5% shares | Q2 2026 |
| Avidity Partners Management LPHedge fund | 0.8% | $5.3M | 98,000 | +104.2% shares | Q2 2026 |
| Platinum Investment Management LtdAsset manager | 1.2% | $4.8M | 90,363 | +35.1% shares | Q2 2026 |
| Boxer Capital Management, LLCHedge fund | 0.3% | $4.0M | 75,000 | +0.0% shares | Q2 2026 |
| Cormorant Asset Management, LPHedge fund | 0.2% | $4.0M | 75,000 | -57.1% shares | Q2 2026 |
| Buckland Partners Management Co LLCHedge fund | 1.3% | $2.7M | 50,000 | +0.0% shares | Q2 2026 |
| DAFNA Capital Management LLCHedge fund | 0.5% | $2.5M | 46,500 | +0.0% shares | Q2 2026 |
| Jones Hill Capital LPHedge fund | 0.5% | $2.2M | 40,567 | -59.7% shares | Q2 2026 |
| PSquared Asset Management AGHedge fund | 0.7% | $2.0M | 37,200 | +6.3% shares | Q2 2026 |
| Flax Pond Capital, LLCWealth manager | 1.4% | $1.8M | 37,000 | +2.8% shares | Q2 2026 |
| DCF Advisers, LLCAsset manager | 0.5% | $1.7M | 32,100 | +16.7% shares | Q2 2026 |
The 30 largest of 34 positions, by value. Each manager counts with its latest 13F (Q3 2026: 1, Q2 2026: 33). Screen GPCR in the grand portfolio →
GPCR stock trades by members of Congress
Members of Congress have disclosed 1 GPCR trade since 2023, 0 purchases and 1 sale in the past year; the latest was Thomas R. Carper (D-DE), selling $1K–15K on Oct 4, 2023.
| Filed | Member | Trade | Amount | Traded | Since |
|---|---|---|---|---|---|
| Nov 2, 2023 | Thomas R. CarperD-DE · Senate | Sale | $1K–15K | Oct 4, 2023 | -59.4% |
GPCR questions and answers
Are insiders buying GPCR stock?
No open-market insider purchases or sales of GPCR were filed in the last 90 days.
Which hedge funds own GPCR?
34 13F filers hold GPCR among their 50 largest positions, worth $1.5B combined, including Behzad Aghazadeh, James Flynn and Julian and Felix Baker. The biggest bets by portfolio weight are NEXTBio Capital Management LP (7.7%), Bvf Inc/il (4.6%) and B Group, Inc. (4.3%). In their latest 13Fs, 0 managers opened a new position and 15 added to one.
Has Congress traded GPCR?
Members of Congress have disclosed 1 GPCR trade since 2023, 0 purchases and 1 sale in the past year; the latest was Thomas R. Carper (D-DE), selling $1K–15K on Oct 4, 2023.
Who is the largest holder of GPCR?
Among 13F filers, Behzad Aghazadeh reports the largest GPCR position, $351.8M (6,555,555 shares) in its Q2 2026 13F. The biggest bet by portfolio weight is NEXTBio Capital Management LP's: 7.7% of its portfolio.
Cite or share this
Free to use with a link back. The data updates every filing day.